OraSure Technologies Inc
OraSure Technologies Inc develops and markets rapid diagnostic tests and related products for the detection of infectious diseases, primarily HIV, and provides point-of-care diagnostic solutions for healthcare professionals and consumers.
Business. OraSure Technologies Inc (OSUR.O) is a healthcare services and equipment company that operates within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, focusing on medical devices and related supplies. It is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not provided in the available data.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
OraSure Technologies Inc (OSUR.O) is a healthcare services and equipment company that operates within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, focusing on medical devices and related supplies. It is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not provided in the available data.
OraSure Technologies Inc exhibits a strong liquidity position, with $199.28 million in cash and equivalents and a current ratio of 6.58, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is effectively zero, as it holds only $163,000 in long-term debt against $340.83 million in total equity, suggesting a conservative capital structure. However, the company reported negative operating and free cash flows of -$49.02 million and -$60.32 million, respectively, which may signal operational inefficiencies or high capital expenditures.
Profitability metrics for OraSure are underperforming relative to industry norms. The company recorded a net loss of $68.73 million and an operating loss of $71.97 million, resulting in a return on equity of -20.17% and a return on assets of -17.05%. These figures are significantly below the industry's median profitability metrics, indicating a need for operational improvements or cost restructuring to align with sector performance.
OraSure's revenue is concentrated in a single business segment focused on rapid diagnostic tests and related products, with no disclosed geographic diversification in the provided data. This concentration may expose the company to higher risk if demand for its primary product line fluctuates or if regulatory changes impact its operations.
The company's growth trajectory appears to be under pressure, with a net loss in the most recent reporting period and no clear indication of revenue growth in the outlook. Analysts have assigned a mean price target of $4.00, with a median and high target also at $4.00, and a mean recommendation of 2.00 (indicating a "Hold"). These signals suggest limited upside potential in the near term and a cautious investor sentiment.
Risk factors for OraSure include its negative operating and free cash flows, which could limit its ability to fund operations or invest in growth without external financing. The company has not disclosed any immediate dilution risks, and its liquidity position remains strong, with no filing-based flags detected. However, the absence of positive cash flow generation may necessitate future capital raises, which could introduce dilution risk if not managed carefully.
Recent events, as reflected in the financial snapshot, show a continuation of operational losses and negative cash flows. No specific filings or transcripts are cited in the provided data, but the financial results suggest a challenging operating environment for the company.
- OraSure Technologies Inc has a strong liquidity position with $199.28 million in cash and equivalents and a current ratio of 6.58.
- The company is experiencing significant operational losses, with a net loss of $68.73 million and an operating loss of $71.97 million.
- OraSure's profitability metrics, including a return on equity of -20.17%, are well below industry medians.
- The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
- Analysts have assigned a mean price target of $4.00 and a "Hold" recommendation, indicating limited near-term upside potential.
- OraSure's negative operating and free cash flows may necessitate future capital raises, which could introduce dilution risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,85 |
| Revenue | —no estimate | —no estimate | 118,3M USD |
| Operating income | —no estimate | —no estimate | -55,6M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- OraSure Technologies Inc Market data — financials · 2026-05-28
- OraSure Technologies Inc Market data — analyst estimates · 2026-05-28
- OraSure Technologies Inc Market data — ESG · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2024-06-300,00 %$31M
- Brokerage Firms · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Carrie Eglinton MannerPresident, Chief Executive Officer, Director
Insider activity
- Director · Common StockOther 46 106 · 2026-06-03
- Director · Common StockOther 46 106 · 2026-06-03
- Director · Common StockOther 46 106 · 2026-06-03
- Director · Common StockOther 46 106 · 2026-06-03
- Director · Common StockOther 46 106 · 2026-06-03
- Director · Common StockOther 46 106 · 2026-06-03
- Director · Common StockBought 25 000 @ $2,99$75K · 2026-05-14
- Director · Common StockOther 28 406 @ $3,02$86K · 2026-05-13
- Director · Common StockBought 25 000 @ $3,02$76K · 2026-05-13
- Director · Common StockOther 22 888 @ $3,02$69K · 2026-05-13
- Director · Common StockOther 21 305 @ $3,02$64K · 2026-05-13
- Director · Common StockOther 33 661 · 2026-05-12
- Director · Common StockBought 25 000 @ $2,98$74K · 2026-05-12
- Director · Common StockOther 5 246 @ $3,10$16K · 2026-03-26
- Director · Common StockOther 1 416 @ $3,10$4K · 2026-03-26
- Director, President & CEO · Common StockBought 32 300 @ $2,93$95K · 2026-03-20
- Chief Financial Officer · Common StockBought 32 300 @ $2,93$95K · 2026-03-20
- Director, President & CEO · Common StockBought 22 022 @ $3,00$66K · 2026-03-13
- Chief Financial Officer · Common StockBought 22 021 @ $3,00$66K · 2026-03-13
- Chief Financial Officer · Common StockOther 88 348 · 2026-03-02
- SVP Finance & CAO · Common StockOther 42 982 · 2026-03-02
- Director, President & CEO · Common StockOther 355 464 · 2026-03-02
- Director, President & CEO · Common StockOther 122 655 @ $3,04$373K · 2026-03-01
- Chief Financial Officer · Common StockOther 20 745 @ $3,04$63K · 2026-03-01
- Director, President & CEO · Common StockOther 129 032 · 2026-03-01
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): -15.9%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -261.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -261.5%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -39.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -252.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -279.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -154.8%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 63.3%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -38.1%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -16.9%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -10.1%Derived (calculated)
- Net margin (FY 2025-12-31): -59.8%Derived (calculated)
- Gross margin (FY 2025-12-31): 41.9%Derived (calculated)
- Return on equity (FY 2025-12-31): -20.2%Derived (calculated)
- Return on assets (FY 2025-12-31): -17.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 6.58xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.18xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 10.5%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -25.6%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -37.2%Derived (calculated)
- Total assets (annual): USD 403.17MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
- Operating cash flow (annual): USD -49.02MSEC XBRL filing
- Cost of revenue (annual): USD 66.82MSEC XBRL filing